Now she is going to give him a job rebuilding the econ. He knows how to get jobs she said. Here is how Bill will proceed:
1. Get him a full time airplane to ride around in with interns
2. Go visit all the unions and get them the checkoff they want
3. Invite more illegals in because they are good for the econ
4. Put more regs on business, particularly about trans people
5. Make sure the banks give mortgages to insolvent people.
6. Forgive all college debt
7. Get unemployment comp for illegals
8. Tax the #$%$ out of business so they learn they lesson
could be the good phase 3 news combined with some short covering and maybe big money deciding it's time to get back into big cap bio techs?
Sentiment: Strong Buy
otech Regeneron Pharmaceuticals’ (REGN) core ophthalmology business still has huge upside as its Eylea sales grow in treating a variety of eye diseases, says RBC Capital. RBC also says that a legal settlement with Amgen (AMGN) over Praluent, a drug intended to lower bad LDL cholesterol, would be a positive.
Most of Regeneron’s sales come from Eylea, launched in 2011 to treat age-related vision loss in the elderly. Regeneron aims to build sales of Eylea in the market for treating diabetic macular edema (DME), a cause of blindness in working-age people, as well as a related eye disease affecting older people.
“Turning DME into a $2 billion to $3 billion market opportunity is important and likely,” Adnan Butt, an RBC Capital analyst, said in a research report Tuesday. In DME, Eylea competes with Roche Holding’s (RHHBY) Lucentis.
Regeneron typically reports earnings in early May. Roche, Novartis (NVS) and Bayer (BAYRY) report earnings on April 19, 21 and 26, respectively, and their commentary could provide insights into Eylea’s growth, says RBC’s Butt.
He says that consensus expectations for the recently launched cholesterol drug Praluent, which had only $7 million in December-quarter sales, still need to come down. Amgen makes a rival drug called Repatha. In March, a federal jury upheld the validity of two Amgen patents related to the cholesterol drug, dealing a blow to Regeneron and partner Sanofi (SNY).
“A settlement with Amgen could be a positive,” Butt said in the report. He rates Regeneron stock outperform, with a price target of 668. Regeneron stock was up more than 1.5% in early afternoon trading in the stock market today, near 402.50.
Amgen reports earnings on April 28, followed by Sanofi on April 29. Their earnings calls could provide reads on the status of Praluent litigation, says Butt.
Regeneron stock has plunged 26% in 2016 amid a broad sell-off in biotech stocks, including Celgene (CELG) and Gilead Sciences (GILD).
Regeneron shares touched a six
This saturday I saw lot more anxiety on the face of the shorts. They know that the market will rebound sharply in particular the tech sector and the bio tech sector.They know that they will sink if they hold on to their short positions and this is particularly true via via the margin holdings and the puts and the hedge funds are nervous too. The hedge funds want to jump right back in as well. I am telling you if you are interested this is the best time to get in. The hostile lies canard that this is bad, that is bad or Britian will leave EU (so what) has us the longs little edgy but it is only a televison ploy and yes lies canard and as I accumulate I have a glow plus a glee on my not too good loking face. I would not be surprised if the dow jumps 678 points or more next week and so will NASDAQ and S & P . They will rebound very very sharply as well.
Sentiment: Strong Buy
I would hold out until after they pull the cholesterol drug from the shelf.. then you are certain to get it for at least 30% less. It's going to happen, it's just a matter of when.
=== Given that Regeneron shares have dropped considerably in the past year and the company could potentially have four top selling drugs in its product lineup by the end of 2017, picking up this company's stock on sale may be smart.
I agree, Every time it has dropped below the lower Bollinger Band in the last year has been a buying opportunity. Usually good for 30 to 40 points in a month.
He could be a Regeneron laid off previous employee that is still bitter. You have these losers pretty much living on each board. Pathetic. I put him on the ignore list.
to make a bid for all of REGN at these depressed prices? 25% premium to current price would have buy out price at $466
Sentiment: Strong Buy
Oh, It seems the disgust for you is not limited to this MB, rather all . You must be real popular come summer BBQ's. What a global fricken' dooshbag. Loser.
baily im not selling.I added more I never thought todays news would be that big. I guess its the best in its field.